Historical revenue CAGR of 5.6% (2022–2025: $79.99B to $94.19B) and analyst 1…
Trailing EBIT margin of 25.8% is robust for a diversified healthcare conglome…
Beta of 0.206 is well outside the CAPM-usable band (0.6–1.4), so sector midpo…
Suurin riski
Stelara biosimilar competition is a material near-term headwind to Innovative Medicine …
Ongoing talc litigation creates contingent liability uncertainty; large adverse judgmen…
IRA drug price negotiation mechanism creates structural margin pressure on high-revenue…
Muutos
All four core assumptions are unchanged from the prior day model. Spot price has moved modestly lower ($253.91 to $25…
Arvostusoletukset
CLAUDE
DEEPSEEK
GEMINI
GPT
GROK
Liikevaihdon CAGR 5V
5.5%
4.2%
5.5%
5.0%
5.5%
EBIT-marginaalitavoite
27.0%
25.5%
26.5%
27.0%
26.0%
WACC
7.5%
6.0%
8.0%
8.0%
9.0%
Terminaalikasvu
2.5%
2.0%
2.0%
2.0%
2.0%
Mitä markkinahinta edellyttäisi?
Oletus
AI-konsensus
Markkinahinta implikoi
Liikevaihdon CAGR (5v)
5.5%
8.5%
+3.0pp
EBIT-marginaalitavoite
26.5%
33.5%
+7.0pp
WACC
8.0%
7.1%
-0.9pp
Perustuu spot-hintaan $253.28 ja raakaan DCF-malliin (ilman kattoja ja kalibrointia).
Tunnusluvut
EBIT-marginaali25.8%
EBITDA-marginaali34.4%
ROE19.7%
Nettovelka / EBITDA0.8x
P/E37.9x
EV / EBITDA18.7x
P/B7.2x
Analyytikkojen vaihteluväli190.00 – 320.00
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and re
Tilaa sähköpostiuutisetIlmainen · Ei roskapostia · Peruuta milloin vain · Tietosuoja
AI Investor Barometer · 2026-10-16
Kaikki sisältö on tekoälymallien tuottamaa ja voi sisältää virheitä. Tämä on kokeellinen työkalu — ei sijoitusneuvontaa, -tutkimusta eikä -suositusta. Tietoa · Metodologia · Käyttöehdot · Tietosuoja
4 viidestä AI-mallia on negatiivisia JNJ.
Huomioitavaa: Litigation overhang and settlement cost uncertainty related to legacy talc pr...
AI-konsensusarvio 231.59 8.6% alle nykyhinnan.
Mallien yksimielisyys on korkea (0.76).
Analyytikkokonsensus: 278.86 (AI -17.0%).
Pessimistinen (min)
$190.65
-24.7%
Perus (mediaani)
$231.59
-8.6%
Optimistinen (max)
$260.36
2.8%
Bear/Base/Bull: mallien oma haarukka (12 kk:n arvot)